CD4 and neoplasm: To test whether the tumor-specific CD4 T cells were the source of the crucial IFNγ, we treated tumor-bearing mice with IFNγ deficient Marilyn CD4 T cells and found that, similarly to the IFNγ blocking experiment, most of the antitumor effect was lost (Fig. 6C).